A previous article by Vaping Post discussing the acquisition said that Fertin is the “world’s biggest contract development and manufacturing organization for nicotine chewing gum” and “also helps produce tablets, gum and lozenges used for pain medication, vitamins, cough treatments, and sleeping aids.”
Another step towards PMI’s goal of becoming a mostly smoke-free by 2025
Finally, PMI announced the acquisition for an enterprise value of DKK 5.1 billion (approximately USD 820 million1). This move supports the tobacco company’s goal of becoming a mostly smoke-free business by 2025, creating growth opportunities beyond tobacco.
“The acquisition of Fertin Pharma will be a significant step forward on our journey toward delivering a smoke-free future—enhancing our smoke-free portfolio, notably in modern oral, and accelerating our progress in beyond nicotine,” stated Jacek Olczak, Chief Executive Officer.
“Both PMI and Fertin share a commitment to science and consumer-centric innovations for better living, and I am delighted we have reached this agreement. Fertin’s diverse portfolio of technologies, evolving business mix, and world-class expertise will enrich our innovation pipeline and capabilities, providing speed and scale in oral delivery to support our 2025 goals of generating more than 50% of our net revenues from smoke-free products and at least USD 1 billion from products beyond nicotine.”